English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 3/5 criteria met. Data as of 14/10/2026.
- ❌ Price trend failed
- ✅ Growth passed
- ✅ Debt passed
- ✅ P/E passed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: 26.77%
Price change 2019 → 2020: 29.81%
Price change 2020 → 2021: 57.89%
Price change 2021 → 2022: -33.64%
Price change 2022 → 2023: 16.89%
Price change 2023 → 2024: -26.86%
Price change 2024 → 2025: 11.48%
Price change 2025 → 2026: -9.10%
Price change 2026 (year to date): -10.07%
Financial growth
Revenue CAGR (8 years): 5.23%
Earnings CAGR (8 years): 6.76%
Growth status: positive trend (>1%/yr) in revenue and earnings.
Debt
Debt-to-equity ratio: 0.03
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 14.43
P/E < 25.0 (maximum threshold).
Correction (6 months)
Current correction: 9.64% from the high over 6 months.
Insufficient correction (< 10.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="VETO.PA" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Vetoquinol S.A. | 16.2 | 0.03 | +4.2 % | 🔒 |
| Clariane SE | 574.8 | 2.16 | +12.4 % | – |
| DocMorris AG | – | 0.71 | +5.7 % | – |
| Emeis | – | 6.11 | +11.4 % | – |
| Fleury S.A. | 16.6 | 1.05 | +16.2 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Vetoquinol S.A. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 477 m | 21.4 m | 4.5 % | n/a |
| 2021 | 581 m | 70.1 m | 12.1 % | +21.9 % |
| 2022 | 602 m | 53.5 m | 8.9 % | +3.6 % |
| 2023 | 590 m | 61.9 m | 10.5 % | -1.9 % |
| 2024 | 601 m | 65.4 m | 10.9 % | +1.9 % |
| 2025 | 586 m | 63.9 m | 10.9 % | -2.5 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Vetoquinol S.A. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 69.0 m | 93.7 m | 147 m | 206 m | 221 m |
| Total Debt | 15.4 m | 17.4 m | 17.6 m | 21.1 m | 15.3 m |
| Net Debt | -53.6 m | -76.3 m | -130 m | -185 m | -206 m |
| Equity | 441 m | 485 m | 527 m | 576 m | 591 m |
| Total assets | 625 m | 652 m | 692 m | 744 m | 764 m |
| Operating cash flow | 89.7 m | 62.9 m | 89.4 m | 85.8 m | 72.1 m |
| Investments (capex) | 32.4 m | 22.5 m | 14.9 m | 14.5 m | 20.7 m |
| Free cash-flow | 56.8 m | 39.9 m | 70.4 m | 68.1 m | 51.3 m |
| Share buybacks | 0 | 0 | 0 | 2.9 m | 13.0 m |
| Dividends paid | 5.9 m | 9.5 m | 9.5 m | 10.1 m | 10.4 m |
Amounts in EUR, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Valuation and competitors
Vetoquinol S.A. compared with its sector on the same exchange and with its main competitors.
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 06/11/2026. Competitors: comparable companies named by the data provider.
Dividends and earnings
Vetoquinol S.A.: dividend history, last distributions, stock splits and earnings releases.
Annual dividend per share (EUR), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.
Latest ex-dividend dates
| Ex-dividend | Amount | Payment |
|---|---|---|
| 03/06/2026 | 0.930 EUR | 05/06/2026 |
| 04/06/2025 | 0.890 EUR | 06/06/2025 |
| 04/06/2024 | 0.850 EUR | 06/06/2024 |
| 02/06/2023 | 0.800 EUR | 06/06/2023 |
| 03/06/2022 | 0.800 EUR | 07/06/2022 |
| 04/06/2021 | 0.500 EUR | 08/06/2021 |
| 02/06/2020 | 0.380 EUR | 04/06/2020 |
| 31/05/2019 | 0.480 EUR | 04/06/2019 |
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Vetoquinol S.A.
What is the Vetoquinol S.A. share price?
Latest recorded price: 88.40 EUR on 06/11/2026, for a market cap of 1.1 bn USD.
What is the revenue of Vetoquinol S.A.?
586 m USD for fiscal year 2025, with net income of 63.9 m USD (net margin 10.9 %).
Does Vetoquinol S.A. pay a dividend?
Yes. Latest dividend: 0.930 EUR per share, ex-dividend on 03/06/2026. Over 12 months: 0.930 EUR. Yield on the latest known price: 1.1 %.
What is the P/E ratio of Vetoquinol S.A.?
Trailing 12-month P/E of 16.8.
Is Vetoquinol S.A. stock eligible for the French PEA?
Likely: the company is headquartered in the European Union or the European Economic Area (ISIN FR0004186856) and the stock is listed on a European exchange. The institution holding the PEA confirms eligibility.
How many employees does Vetoquinol S.A. have?
2,519 full-time employees according to the latest published profile.
Who runs Vetoquinol S.A.?
Dominique Derveaux is the company's chief executive.